Aktis Oncology, Inc. (AKTS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$15.19

From 52W high−53.12%

Volume353421.00

Market cap$840.41M

P/E (TTM)—

P/S (TTM)83.5x

Div yield—

Key dataOct 19, 2026

Open

$15.19

From 52W high

−53.12%

Volume

353421.00

Market cap

$840.41M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.3x

P/E (TTM)

—

RSI (14)

20.6

MomentumView details →

1D Return

+0.33%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.3x

EV/Sales

33.2x

P/S (TTM)

83.5x

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

84.78%

Net Margin

−727.04%

EBITDA Margin

−772.77%

ROE (TTM)

−15.09%

ROA (TTM)

−13.12%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+336.92%

EPS CAGR 3Y

+5.56%

EBITDA YoY

—

MomentumView details →

1D Return

+0.33%

YTD Return

—

1Y Return

—

RSI (14)

20.6

vs 50D SMA

−30.78%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

16.33x

Quick Ratio

16.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.44

EPS Surprise

−2.17%

Beats (12Q)

0/12

Next Q EPS Est

−$0.49

Avg Surprise (4Q)

−2.17%

Rev Surprise

25.44%

Financials snapshotView financials →

Revenue (TTM)

10.06M

Net Income (TTM)

−73.14M

Op. CF (TTM)

−75.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

Aktis Oncology initiated the Phase 1b BActinium-2 clinical trial of AKY-2519 in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors.19d ago

Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.68d ago

Similar companies

Arbutus Biopharma CorporationABUS Kura Oncology, Inc.KURA MoonLake ImmunotherapeuticsMLTX CANbridge Pharmaceuticals Inc.01228.HK SL Science Holding Limited Ordinary SharesSLBT SpyGlass Pharma, Inc. Common StockSGP Find similar companies →

Latest newsMore news →

Aktis Oncology initiated the Phase 1b BActinium-2 clinical trial of AKY-2519 in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors.19d ago Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.68d ago